Reasons IVC Filter Cases Against Bard Continue To Grow

by Terry Bryant

As IVC filter cases against Bard continue to mount, it’s becoming clear to all involved that the device manufacturer was likely acting recklessly, even deceptively, in its handling of the implant. Initially considered a safe, frontline treatment for people who cannot receive blood thinning medication, many doctors are now worried about the device’s long-term safety.

The implant is designed to intercept blood clots in the inferior vena cava, a large vessel that supplies deoxygenated blood to the heart. When it works properly, it prevents embolisms from reaching the heart and causing an immediate cardiac emergency. However, the implant itself is capable of migrating and behaving like an embolism itself, especially if it reaches the heart. There have also been many claims of the implant fracturing and puncturing through the vessel, causing serious internal bleeding.

Researchers now believe the device should be removed as soon as the risk of pulmonary embolism is no longer present. This is typically between 29 and 54 days, and if the device is not removed around then, the risk of severe complications will continue to grow.

IVC filter cases against Bard assert that the implant manufacturer knew about these complications to some extent, but ignored them for the sake of profit. Released court documents suggest that the company may have known about the implant’s risks as far back as 2002, which is several years before the device was approved for use. That will likely spell major trouble for the company, though it may only be a small comfort to those already badly harmed by the device.